A concentrated sweet-orange extract whose most dependable effect is a small drop in cholesterol, with weaker, less consistent signals for blood pressure, blood sugar, and artery-lining function. Safety is reassuring; the main cautions are theoretical drug interactions and untested use in pregnancy. Benefits are modest and unproven for long-term heart health or lifespan. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL cholesterol | < 2.6 mmol/L (< 100 mg/dL) | Primary lipid target most consistently improved |
| Apolipoprotein B (ApoB) | < 0.9 g/L | Counts atherogenic particles; more precise than LDL alone |
| Total cholesterol | < 5.2 mmol/L (< 200 mg/dL) | Broad lipid overview; secondary hesperidin target |
| Triglycerides | < 1.1 mmol/L (< 100 mg/dL) | Fat fraction modestly lowered by hesperidin |
| Fasting glucose | 4.4–5.0 mmol/L (79–90 mg/dL) | Detects small glycemic benefit |
| HbA1c | < 5.4% | Averages blood sugar over ~3 months |
| High-sensitivity C-reactive protein | < 1.0 mg/L | Tracks the vascular-inflammation benefit |
| Blood pressure | < 120/80 mmHg | Captures any modest pressure-lowering effect |
Cadence: Baseline, recheck at 8–12 weeks, then every 6–12 months